EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Transthyretin Amyloid Cardiomyopathy: Contemporary Pharmacological Management

María Teresa Basurte-Elorz, Gemma Lacuey-Lecumberri, Nerea Mora-Ayestarán

European Cardiology Review · 2026-11-02

DOI: 10.15420/ecr.2026.01 ↗
AbstractBibliografische Angaben

Abstract

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive infiltrative cardiomyopathy increasingly recognised as a cause of heart failure. Advances in the understanding of its pathophysiology have enabled the development of targeted therapies, making ATTR-CM a paradigm of precision medicine in cardiology. Currently approved disease-modifying therapies, including two stabilisers (tafamidis and acoramidis) and one gene-silencing agent (vutrisiran), slow disease progression and reduce hospitalisations and mortality, particularly when initiated early. Because these therapies do not reverse established amyloid deposition, supportive management remains a critical component of care and presents distinct challenges. These include universal anticoagulation in AF, careful diuretic management, the benefits of sodium–glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonists, and limited tolerance to other foundational heart failure therapies. On-going intensive research is expanding the therapeutic landscape, with several Phase III trials evaluating next-generation silencers, gene-editing strategies and amyloid-removal therapies. While these advances hold promise for disease reversal and prevention, important unresolved issues arise, including optimal treatment selection, monitoring strategies and economic sustainability.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →